REAL-WORLD USE OF BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN US PATIENTS WITH ANKYLOSING SPONDYLITIS: PERSISTENCE, FACTORS ASSOCIATED WITH DISCONTINUATION, AND DOSING PATTERNS

被引：0

作者：

Dubreuil, M. ^{[1
]}

Walsh, J. A. ^{[2
,3
]}

Deodhar, A. ^{[4
]}

Gensler, L. S. ^{[5
]}

Curtis, J. R. ^{[6
]}

Anjohrin, S. ^{[7
]}

Pilipczuk, O. ^{[8
]}

Tepie, Feudjo M. ^{[9
]}

Beaty, S. ^{[8
]}

Morup, M. ^{[10
]}

Taieb, V ^{[11
]}

Welby, S. ^{[8
]}

机构：

[1] Boston Univ, Sch Med, Boston, MA 02118 USA

[2] Salt Lake City Vet Affairs Hlth, Salt Lake City, UT USA

[3] Univ Utah Hlth, Salt Lake City, UT USA

[4] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[5] Univ Calif San Francisco, San Francisco, CA 94143 USA

[6] Univ Alabama Birmingham, Birmingham, AL USA

[7] UCB Pharma, Tallahassee, FL USA

[8] UCB Pharma, Brussels, Belgium

[9] UCB Pharma, Smyrna, GA USA

[10] UCB Pharma, Copenhagen, Denmark

[11] UCB Pharma, Colombes, France

来源：

VALUE IN HEALTH | 2023年 / 26卷 / 06期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

RWD136

引用

页码：S386 / S387

页数：2

共 50 条

[21] INFECTIOUS COMPLICATIONS AS A REASON FOR THE CANCELLATION OF BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
Aronova, E.
Gridneva, G.
Kudryavtceva, A.
Dydykina, I.
Lukina, G.
OSTEOPOROSIS INTERNATIONAL, 2021, 32 (SUPPL 1) : S250 - S250
[22] Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
Tawaratsumida H.
Setoguchi T.
Arishima Y.
Ohtsubo H.
Akimoto M.
Ishidou Y.
Nagano S.
Taketomi E.
Sunahara N.
Komiya S.
BMC Research Notes, 10 (1)
[23] IMPACT OF BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN LIPID PROFILE OF PSORIATIC ARTHRITIS PATIENTS
Guajardo-Aldaco, Andrea L.
Galarza-Delgado, Dionicio A.
Azpiri-Lopez, Jose R.
Colunga-Pedraza, Iris J.
Cardenas-de la Garza, Jesus A.
Arvizu-Rivera, Rosa I.
Elizondo-Benitez, Maria F.
Gonzalez-Gonzalez, Valeria
ACTA DERMATO-VENEREOLOGICA, 2024, 104
[24] Methotrexate Use and the Risk for Cardiovascular Disease Among Rheumatoid Patients Initiating Biologic Disease-Modifying Anti-Rheumatic Drugs
Xie, Fenglong
Chen, Lang
Levitan, Emily
Muntner, Paul M.
Curtis, Jeffrey R.
ARTHRITIS & RHEUMATOLOGY, 2018, 70
[25] Use of biological disease-modifying anti-rheumatic drugs in patients with concurrent rheumatic disease and hepatitis B
King, L. K.
Lee, A.
Anandacoomarasamy, A.
INTERNAL MEDICINE JOURNAL, 2012, 42 (05) : 523 - 531
[26] Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis
Rosenberg, Vered
Amital, Howard
Chodick, Gabriel
Faccin, Freddy
Gendelman, Omer
DRUGS & AGING, 2024, 41 (08) : 685 - 697
[27] The influence of medication beliefs and other psychosocial factors on early discontinuation of disease-modifying anti-rheumatic drugs
Wong, M.
Mulherin, D.
MUSCULOSKELETAL CARE, 2007, 5 (03) : 148 - 159
[28] The influence of medication beliefs and other psychosocial factors on early discontinuation of disease-modifying anti-rheumatic drugs
Wong, MM
Mulherin, D
RHEUMATOLOGY, 2005, 44 : I95 - I96
[29] Effectiveness and safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis: real-world data from the KOBIO Registry
Koh, J. H.
Lee, S-K
Kim, J.
Kim, H-A
Shin, K.
Min, J-K
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (02) : 269 - 278
[30] Leflunomide discontinuation in rheumatoid arthritis and influence of associated disease-modifying anti-rheumatic drugs: a survival analysis
Rodriguez-Rodriguez, L.
Jover-Jover, J. A.
Fontsere, O.
Pena-Blanco, R. C.
Leon, L.
Fernandez-Gutierrez, B.
Abasolo, L.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2013, 42 (06) : 433 - 436

← 1 2 3 4 5 →